Silo Pharma's AI subsidiary QwikAgents has joined NVIDIA's Developer Program, gaining access to NVIDIA's software ecosystem, tools, and technical support to accelerate development of its autonomous AI agent platform for business process automation.
The partnership aims to help QwikAgents build scalable AI solutions for enterprises, while Silo Pharma separately advances development of an intranasal psychedelic-based PTSD treatment candidate.
What happened
Silo Pharma announced on July 7 that QwikAgents, its wholly owned subsidiary, joined the NVIDIA Developer Program to support its AI agent integration platform. The program grants QwikAgents access to NVIDIA's AI software ecosystem, development tools, technical resources, and optimization support.
Why it matters
QwikAgents builds a platform to automate complex business processes using autonomous AI agents that reason, execute tasks, and connect with enterprise systems. NVIDIA's resources are intended to accelerate platform development as the company expands solutions for organizations seeking scalable AI-driven operations.
What to watch
Separately, on June 29, Silo Pharma partnered with Resyca to evaluate its microchip-based nasal spray technology for SPC-15, its lead intranasal treatment for post-traumatic stress disorder, assessing device reliability and formulation stability over 30 days.
Ask the AI about this article →
Silo Pharma operates as a developmental-stage biopharmaceutical company that combines psychedelic research with traditional therapeutics. The company has two distinct business threads: its core psychedelic drug development work targeting conditions including PTSD, Alzheimer's disease, multiple sclerosis, and chronic pain, and its AI subsidiary QwikAgents, which builds autonomous agent technology for enterprise automation. The NVIDIA partnership announced on July 7 represents an effort to accelerate QwikAgents' technical capability by embedding it within NVIDIA's broader ecosystem. On the pharmaceutical side, the June 29 announcement of the Resyca partnership for evaluating its SPC-15 nasal spray formulation signals progress toward regulatory submission, with the company pursuing an FDA 505 pathway. The nose-to-brain delivery approach is intended to concentrate drug effects in the brain while reducing systemic side effects.
For example, today's edition would include:
AI-summarized, only the topics you pick — one digest a day via Email, Slack, or Discord.
Free · takes 30 seconds · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. Q&As are published on this page for other readers too.
Visko raised $10 million in pre-seed funding from Llama Ventures and opened public access to its first foundat…
U.S. markets ended August higher, with the S&P 500 up 2.6% and the Nasdaq up 3.9%
Neurovia AI, an Abu Dhabi-based company, is pitching Saudi security agencies software that it says can compres…
AI company Runway has unveiled Solaris, the first model in a new category it calls "Interface World Models." I…
John Deere introduced JD, a conversational AI tool that lets farmers ask open-ended questions about their hist…
Nvidia CEO Jensen Huang said on Fox Business that AI is creating 'hundreds of thousands' of jobs, including in…
